Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 2
1997 1
1998 1
1999 1
2000 1
2001 1
2003 1
2006 2
2007 5
2008 1
2009 2
2010 3
2011 1
2012 5
2013 8
2014 12
2015 17
2016 10
2017 3
2018 3
2019 1
2020 2
2021 4
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 26292040

72 results

Results by year

Filters applied: . Clear all
Page 1
Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.
Sonpavde G, Pond GR, Di Lorenzo G, Buonerba C, Rozzi A, Lanzetta G, Necchi A, Giannatempo P, Raggi D, Matsumoto K, Choueiri TK, Mullane S, Niegisch G, Albers P, Lee JL, Kitamura H, Kume H, Bellmunt J. Sonpavde G, et al. Clin Genitourin Cancer. 2016 Dec;14(6):494-498. doi: 10.1016/j.clgc.2016.05.001. Epub 2016 May 12. Clin Genitourin Cancer. 2016. PMID: 27262369
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design.
Pond GR, Bellmunt J, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Sonpavde G. Pond GR, et al. Clin Genitourin Cancer. 2015 Feb;13(1):71-9. doi: 10.1016/j.clgc.2014.06.004. Epub 2014 Jun 9. Clin Genitourin Cancer. 2015. PMID: 24993933
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.
Bambury RM, Benjamin DJ, Chaim JL, Zabor EC, Sullivan J, Garcia-Grossman IR, Regazzi AM, Ostrovnaya I, Apollo A, Xiao H, Voss MH, Iyer G, Bajorin DF, Rosenberg JE. Bambury RM, et al. Oncologist. 2015 May;20(5):508-15. doi: 10.1634/theoncologist.2014-0354. Epub 2015 Apr 6. Oncologist. 2015. PMID: 25845990 Free PMC article.
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.
Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Dreicer R, Chen YH, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Bellmunt J. Sonpavde G, et al. Clin Genitourin Cancer. 2015 Apr;13(2):185-92. doi: 10.1016/j.clgc.2014.09.004. Epub 2014 Oct 2. Clin Genitourin Cancer. 2015. PMID: 25458370
Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.
Sonpavde G, Pond GR, Rosenberg JE, Choueiri TK, Bellmunt J, Regazzi AM, Mullane SA, Necchi A, Raggi D, Lee JL, Lee S, Simpson J, Derleth CL, Lin SW, Bajorin DF. Sonpavde G, et al. Clin Genitourin Cancer. 2018 Aug;16(4):e961-e967. doi: 10.1016/j.clgc.2018.03.016. Epub 2018 Apr 6. Clin Genitourin Cancer. 2018. PMID: 29706503 Free PMC article. Clinical Trial.
Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study.
Taguchi S, Nakagawa T, Matsumoto A, Nagase Y, Kawai T, Tanaka Y, Yoshida K, Yamamoto S, Enomoto Y, Nose Y, Sato T, Ishikawa A, Uemura Y, Fujimura T, Fukuhara H, Kume H, Homma Y. Taguchi S, et al. Int J Urol. 2015 Jul;22(7):638-43. doi: 10.1111/iju.12766. Epub 2015 Apr 22. Int J Urol. 2015. PMID: 25903328
72 results